title: [Limits of conventional oral and transdermal medication in Parkinson's disease].
abstract: At the present time, we have effective and potent antiparkinsonian drugs available which allow patients to have an acceptable functional capacity during the early years of Parkinson's disease. Yet, as time goes by, motor and functional deterioration develop, partly due to the presence of motor and non-motor complications. The conventional medication is unable to provide an adequate response if the motor fluctuations are beyond 3-4 hours of duration. At this point, it is reasonable to consider other therapies; among them subcutaneous apomorphine injection must be taken into account due to its simplicity and efficacy and later on, subcutaneous apomorphine infusion. Apomorphine is a very effective and clearly underused drug in the treatment of advanced Parkinson's disease.
authors.affiliation: Fundacion Jimenez Diaz, 28040 Madrid, Espana.
authors.forename: Pedro J
authors.initials: PJ
authors.lastname: García-Ruiz
authors.forename: M Rosario
authors.initials: MR
authors.lastname: Luquin
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001058:Apomorphine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D002394:Catechol O-Methyltransferase; D065098:Catechol O-Methyltransferase Inhibitors; D002986:Clinical Trials as Topic; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D007189:Indans; C031967:rasagiline; D007980:Levodopa; C588010:COMT protein, human; D002394:Catechol O-Methyltransferase; D001058:Apomorphine